Since their invention in the early 2000s, tyrosine kinase inhibitors (TKIs) have gained
prominence as the most effective pathway-directed anti-cancer agents. TKIs have shown …

The smooth muscle cell directly drives the contraction of the vascular wall and hence
regulates the size of the blood vessel lumen. We review here the current understanding of …

Differentiated thyroid carcinomas is associated with an excellent prognosis. The treatment of
choice for differentiated thyroid carcinoma is surgery, followed by radioactive iodine ablation …

Background Lenvatinib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2,
and 3, fibroblast growth factor receptors 1 through 4, platelet-derived growth factor receptor …

These NCCN Guidelines Insights focus on some of the major updates to the 2014 NCCN
Guidelines for Thyroid Carcinoma. Kinase inhibitor therapy may be used to treat thyroid …

Lenvatinib is a multikinase inhibitor of vascular endothelial growth factor (VEGF) receptors 1–
3, fibroblast growth factor receptors 1–4, RET, KIT, and platelet-derived growth factor …

Introduction Lenvatinib is an oral multitargeted tyrosine kinase inhibitor that has shown
efficacy and manageable safety across multiple cancer types. The recommended starting …

While the intratumor microbiome has become increasingly implicated in cancer
development, the microbial landscape of papillary thyroid carcinoma (PTC) is essentially …

Differentiated thyroid carcinoma (papillary and follicular) has a favorable prognosis with an
85% 10‐year survival. The patients that recur often require surgery and further radioactive …

Advanced differentiated thyroid cancer (DTC), defined by clinical characteristics including
gross extrathyroidal invasion, distant metastases, radioiodine (RAI) resistance, and avidity …